Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 54

1.

Efficacy of Tadalafil Therapy and Changes in Oxidative Stress Levels in Male Patients with Lower Urinary Tract Symptoms and Overactive Bladder.

Matsuo T, Miyata Y, Araki K, Mukae Y, Otsubo A, Ohba K, Sakai H.

Low Urin Tract Symptoms. 2019 Aug 13. doi: 10.1111/luts.12283. [Epub ahead of print]

PMID:
31407871
2.

Periodontal Disease in Patients Receiving Dialysis.

Miyata Y, Obata Y, Mochizuki Y, Kitamura M, Mitsunari K, Matsuo T, Ohba K, Mukae H, Nishino T, Yoshimura A, Sakai H.

Int J Mol Sci. 2019 Aug 3;20(15). pii: E3805. doi: 10.3390/ijms20153805. Review.

3.

Pathological Characteristics of Periodontal Disease in Patients with Chronic Kidney Disease and Kidney Transplantation.

Kitamura M, Mochizuki Y, Miyata Y, Obata Y, Mitsunari K, Matsuo T, Ohba K, Mukae H, Yoshimura A, Nishino T, Sakai H.

Int J Mol Sci. 2019 Jul 11;20(14). pii: E3413. doi: 10.3390/ijms20143413. Review.

4.

Stage-specific embryonic antigen-4 is a histological marker reflecting the malignant behavior of prostate cancer.

Nakamura Y, Miyata Y, Matsuo T, Shida Y, Hakariya T, Ohba K, Taima T, Ito A, Suda T, Hakomori SI, Saito S, Sakai H.

Glycoconj J. 2019 Jun 26. doi: 10.1007/s10719-019-09882-2. [Epub ahead of print]

PMID:
31243630
5.

A pilot study to assess the safety and usefulness of combined transurethral endoscopic mucosal resection and en-bloc resection for non-muscle invasive bladder cancer.

Hayashida Y, Miyata Y, Matsuo T, Ohba K, Sakai H, Taba M, Naito S, Taniguchi K.

BMC Urol. 2019 Jun 24;19(1):56. doi: 10.1186/s12894-019-0486-0.

6.

A Review of Oxidative Stress and Urinary Dysfunction Caused by Bladder Outlet Obstruction and Treatments Using Antioxidants.

Miyata Y, Matsuo T, Mitsunari K, Asai A, Ohba K, Sakai H.

Antioxidants (Basel). 2019 May 15;8(5). pii: E132. doi: 10.3390/antiox8050132. Review.

7.

The Pathological Significance and Prognostic Roles of Thrombospondin-1, and -2, and 4N1K-peptide in Bladder Cancer.

Nakamura Y, Miyata Y, Takehara K, Asai A, Mitsunari K, Araki K, Matsuo T, Ohba K, Sakai H.

Anticancer Res. 2019 May;39(5):2317-2324. doi: 10.21873/anticanres.13348.

PMID:
31092423
8.

Effect of salt intake reduction on nocturia in patients with excessive salt intake.

Matsuo T, Miyata Y, Sakai H.

Neurourol Urodyn. 2019 Mar;38(3):927-933. doi: 10.1002/nau.23929. Epub 2019 Feb 1.

PMID:
30706965
9.

Editorial Comment from Dr Miyata et al. to Impact of serum sodium concentration on survival outcomes in patients with invasive bladder cancer without metastasis treated by cystectomy.

Miyata Y, Matsuo T, Sakai H.

Int J Urol. 2019 Mar;26(3):432. doi: 10.1111/iju.13893. Epub 2019 Jan 22. No abstract available.

PMID:
30669187
10.

Oral Intake of Royal Jelly Has Protective Effects Against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial.

Araki K, Miyata Y, Ohba K, Nakamura Y, Matsuo T, Mochizuki Y, Sakai H.

Medicines (Basel). 2018 Dec 20;6(1). pii: E2. doi: 10.3390/medicines6010002.

11.

Anticancer Effects of Green Tea and the Underlying Molecular Mechanisms in Bladder Cancer.

Miyata Y, Matsuo T, Araki K, Nakamura Y, Sagara Y, Ohba K, Sakai H.

Medicines (Basel). 2018 Aug 10;5(3). pii: E87. doi: 10.3390/medicines5030087. Review.

12.

High Consumption of Green Tea Suppresses Urinary Tract Recurrence of Urothelial Cancer via Down-regulation of Human Antigen-R Expression in Never Smokers.

Yasuda T, Miyata Y, Nakamura Y, Sagara Y, Matsuo T, Ohba K, Sakai H.

In Vivo. 2018 Jul-Aug;32(4):721-729. doi: 10.21873/invivo.11300.

13.

Pathological significance and prognostic roles of densities of CD57+ cells, CD68+ cells, and mast cells, and their ratios in clear cell renal cell carcinoma.

Nakanishi H, Miyata Y, Mochizuki Y, Yasuda T, Nakamura Y, Araki K, Sagara Y, Matsuo T, Ohba K, Sakai H.

Hum Pathol. 2018 Sep;79:102-108. doi: 10.1016/j.humpath.2018.05.007. Epub 2018 May 19.

14.

Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.

Miyata Y, Matsuo T, Nakamura Y, Yasuda T, Ohba K, Takehara K, Sakai H.

Anticancer Res. 2018 Mar;38(3):1629-1635.

PMID:
29491095
15.

Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy.

Matsuo T, Miyata Y, Nakamura T, Satoh K, Sakai H.

Low Urin Tract Symptoms. 2019 Apr;11(2):O65-O70. doi: 10.1111/luts.12218. Epub 2018 Feb 22.

PMID:
29473309
16.

Efficacy and safety of sunitinib alternate day regimen in patients with metastatic renal cell carcinoma in Japan: Comparison with standard 4/2 schedule.

Ohba K, Miyata Y, Yasuda T, Asai A, Mitsunari K, Matsuo T, Mochizuki Y, Matsunaga N, Sakai H.

Asia Pac J Clin Oncol. 2018 Jun;14(3):153-158. doi: 10.1111/ajco.12849. Epub 2018 Jan 31.

PMID:
29383843
17.

Changes in the amount of physical activity in minimally invasive cardiac surgery.

Nakajima M, Totsugawa T, Sakaguchi T, Yuguchi S, Matsuo T, Ujikawa T, Morisawa T, Takahashi T.

J Phys Ther Sci. 2017 Nov;29(11):2035-2038. doi: 10.1589/jpts.29.2035. Epub 2017 Nov 24.

18.

A Mini-Review of Reactive Oxygen Species in Urological Cancer: Correlation with NADPH Oxidases, Angiogenesis, and Apoptosis.

Miyata Y, Matsuo T, Sagara Y, Ohba K, Ohyama K, Sakai H.

Int J Mol Sci. 2017 Oct 22;18(10). pii: E2214. doi: 10.3390/ijms18102214. Review.

19.

Prosultiamine for treatment of lower urinary tract dysfunction accompanied by human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis.

Matsuo T, Miyata Y, Nakamura T, Satoh K, Sakai H.

Int J Urol. 2018 Jan;25(1):54-60. doi: 10.1111/iju.13468. Epub 2017 Oct 1.

20.

Editorial Comment to Nutrient intake and urinary incontinence in Korean women: A propensity score-matched analysis from the Korea National Health and Nutrition Examination Survey data.

Matsuo T, Miyata Y, Sakai H.

Int J Urol. 2017 Nov;24(11):797-798. doi: 10.1111/iju.13449. Epub 2017 Sep 23. No abstract available.

Supplemental Content

Loading ...
Support Center